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Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. AMD is a multifactorial
disorder but complement-mediated inflammation at the level of the retina plays a pivotal role. Oral zinc supplementation
can reduce the progression of AMD but the precise mechanism of this protective effect is as yet unclear. We investigated
whether zinc supplementation directly affects the degree of complement activation in AMD and whether there is a relation
between serum complement catabolism during zinc administration and the complement factor H (CFH) gene or the Age-
Related Maculopathy susceptibility 2 (ARMS2) genotype. In this open-label clinical study, 72 randomly selected AMD patients
in various stages of AMD received a daily supplement of 50 mg zinc sulphate and 1 mg cupric sulphate for three months.
Serum complement catabolism–defined as the C3d/C3 ratio–was measured at baseline, throughout the three months of
supplementation and after discontinuation of zinc administration. Additionally, downstream inhibition of complement
catabolism was evaluated by measurement of anaphylatoxin C5a. Furthermore, we investigated the effect of zinc on
complement activation in vitro. AMD patients with high levels of complement catabolism at baseline exhibited a steeper
decline in serum complement activation (p,0.001) during the three month zinc supplementation period compared to
patients with low complement levels. There was no significant association of change in complement catabolism and CFH
and ARMS2 genotype. In vitro zinc sulphate directly inhibits complement catabolism in hemolytic assays and membrane
attack complex (MAC) deposition on RPE cells. This study provides evidence that daily administration of 50 mg zinc sulphate
can inhibit complement catabolism in AMD patients with increased complement activation. This could explain part of the
mechanism by which zinc slows AMD progression.
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Introduction
Worldwide, age-related macular degeneration (AMD) affects
30–50 million people and is the leading cause of blindness in the
Western world [1–4]. AMD is a complex, multifactorial disease
that manifests clinically as a loss of central vision resulting in an
inability to read, recognize faces or discriminate colors. The
hallmark lesions of early stage AMD are drusen, which are
pathological deposits of extracellular material that form between
the retinal pigment epithelium and Bruch membrane [5]. The late
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e112682
stages of AMD can be separated into geographic atrophy and
neovascular AMD [5]. In patients with neovascular AMD,
choroidal blood vessels invade the central retina and subretinal
space causing a rapidly progressive loss of vision [5]. Although the
neovascular AMD accounts for 10% of all AMD patients, it is
responsible for the majority of AMD-related severe visual
impairment [6–9]. Despite the beneficial effects of intraocular
injections of vascular endothelial growth factor A (VEGF-A)
inhibitors [10–11], a large percentage of neovascular AMD
patients continue to lose vision [12–13]. In patients with
geographic atrophy, loss of the RPE and photoreceptor cells in
the central retina result in a progressive decline of vision at a much
slower rate than neovascular AMD [5]. Unfortunately, an effective
therapy for treating geographic atrophy has yet to be developed.
Pivotal studies performed during the past decade have changed
our understanding of the molecular mechanisms underlying
AMD. These findings have led to the exploration of a new
therapeutic paradigm for managing AMD, namely the targeting of
specific molecular components in the complement pathway [14–
15]. The complement system is a major component of innate
immunity with crucial roles in the first line defense against
invading microorganisms, clearance of the apoptotic cells and
modulation of the adaptive immune response [16]. There are
three pathways of complement activation: the classical, the lectin
and the alternative pathway [16]. The most important step of the
alternative complement pathway activation is the formation of
unstable C3 convertase C3bBb, which cleaves C3 to generate the
active fragment C3b. Deposition of C3b on the target surface
triggers the effector molecules C3a, C5a and the membrane attack
complex (MAC), resulting in inflammation and cell lysis. The
discovery that drusen contain proteins of the alternative comple-
ment pathway led to the hypothesis that drusen could be involved
in local complement-mediated inflammation [17–18]. Moreover,
the discovery of a strong association between AMD and genetic
variants in CFH gene, a major inhibitor of the alternative
pathway, provided a second line of evidence in support of the
inflammation model [19–22]. In addition to CFH, several other
AMD risk variants have been found in genes underlying the
alternative pathway [23–26]. A third line of evidence supporting
complement involvement in AMD came from studies that showed
that AMD patients have higher levels of complement activation
products in their blood [27–30]. However, it is likely to be several
years before any of the complement inhibiting drugs will be
approved for routine use in clinical practice, assuming they are
eventually found to be safe and effective.
In 2001, the data collected from the Age-Related Eye Disease
Study (AREDS) revealed that patients who were treated with zinc–
either alone or in combination with vitamins–had reduced
progression to advanced AMD [31]. Based on these results,
AREDS recommends that persons who are older than 55 years of
age and who are at risk for developing advanced AMD should
consider taking vitamin supplements plus zinc [31]. A report
published by the Blue Mountains Eye Study, a population-based
study, confirmed the beneficial effect of zinc in AMD patients [32].
The large population-based Rotterdam Study supported the
hypothesis of biological interactions between the CFH gene
Y402H variant and zinc, b-carotene, lutein/zeaxanthin and
omega-3 fatty acids and between the ARMS2 gene A69S variant
and zinc and omega-3 fatty acids [33]. As a result of these findings,
the Rotterdam Study recommended that clinicians give dietary
advice to young individuals who are at risk for AMD [33]. More
recently, AREDS2 demonstrated that addition of lutein, zeaxan-
thin and omega-3 long-chain polyunsaturated fatty acids to the
AREDS formulation, did not further reduce risk of progression to
advanced AMD [34]. However, exploratory subgroup analyses
demonstrated that addition of lutein and zeaxanthin to the
AREDS formulation, resulted in a significant reduction of
progression to advanced AMD for persons in the lowest quintile
of dietary intake, suggesting different treatment effects within
subgroups of AMD patients [34]. Despite the widespread use of
zinc and antioxidants among AMD patients, the mechanism by
which zinc exerts its beneficial effects in AMD patients has not yet
been identified. The design of optimal and appropriate therapies
require a comprehensive understanding of the factors that drive
and delay pathogenesis of AMD. To add to current knowledge we
designed the present study to investigate whether zinc affects the
activity of the alternative complement pathway in patients with
AMD, which might explain how zinc slows AMD progression in
subgroups of patients with AMD. Secondly, we correlate the
response to zinc supplements to the CFH and ARMS2 genotype
status. Lastly, we conducted an in vitro experiment to evaluate
whether there is a direct effect of zinc on complement activation.
Methods
Study population of the clinical study
This study was performed in accordance with the Declaration of
Helsinki and the Dutch Medical Research Involving Human
Subjects Act. Prior to the study, we obtained approval from the
local ethics committee (Commissie Mensgebonden Onderzoek
regio Arnhem-Nijmegen, April 20th 2010) as well as written
informed consent from all participants. This clinical study was
registered with The Netherlands National Trial Register (number
NTR2605) shortly after recruitment began due to an administra-
tive error. The authors confirm that all ongoing and related trials
for this drug/intervention are registered. The protocol for this trial
and supporting TREND checklist are available as supporting
infromation (Protocol S1 and Checklist S1). The study participants
were enrolled in EUGENDA (www.eugenda.org), a multicenter
database for the clinical and molecular analysis of AMD, between
March 2006 and August 2009. Patients with various stages of
AMD were selected at random from the EUGENDA database and
were included between June 2010 and February 2011. Follow-up
ranged between 14 and 22 months. All data were collected at the
department of Ophthalmology of the Radboud university medical
center. We excluded individuals who had a core body temperature
above 38uC and/or received antibiotics at baseline. In addition,
we excluded patients who were receiving intraocular anti-
angiogenic treatment, individuals with atypical hemolytic uremic
syndrome or membranoproliferative glomerulonephritis type 2
and patients who received local or systemic steroid therapy within
the three months prior to the trial. A total of 72 AMD patients
were included in this study (Figure 1).
Study design
To study the effect of zinc on complement activation in patients
with AMD, 72 AMD patients received a daily oral supplement
containing 50 mg zinc sulphate and 1 mg cupric sulphate in
capsule form. The capsules were to be taken at home for a period
of three months. These components were donated by Sanmed,
Almere, the Netherlands. The 50 mg dose of zinc was lower than
in the original AREDS formulation and was chosen to minimize
the chance of side-effects. Also, we chose zinc sulphate instead of
zinc oxide (as used in the AREDS study), because most over-the-
counter supplements contain zinc sulphate and in addition there is
evidence that the bioavailability may be higher [35,36]. The
primary endpoint of the study was a change in serum complement
catabolism during the three months of zinc supplementation.
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AMD patients have increased serum levels of C3 and the
metabolic byproduct C3d, the most prominent marker of chronic
activation of the alternative complement pathway [30]. To correct
for individual variations in the level of C3, complement activation
was defined as the C3d/C3 ratio as described previously [30].
Anaphylatoxin C5a levels are also elevated in AMD patients and
promote choroidal neovascularization [28,29,37]. In order to
explore downstream inhibitory effects of zinc on complement
catabolism, we additionally measured serum C5a levels during the
study period. The second objective was to study the association of
serum complement catabolism during zinc administration and
genotypes of AMD risk variants in CFH or ARMS2.
During the course of the study, six venous blood samples were
collected. One sample was collected prior to zinc supplementation
and served as the baseline sample. Three samples were collected at
the end of months 1, 2 and 3 of the three-month period of zinc
supplementation. We collected a fifth blood sample two months
after ending the zinc administration (i.e., at the end of month 5) to
check for any reversible effects on complement activation. A final
blood sample was collected in months 14–22. From one month
prior to zinc supplementation through the end of month 5, the
patients were prohibited to take any type of nutritional supple-
ment; from month 5 onwards, the patients were free to take
supplements at their own discretion.
To identify clinical manifestations associated with intermittent
infections, at every visit, we performed a general physical
examination, measured the serum C-reactive protein (CRP) levels
and administered a questionnaire that was aimed at identifying
clinical manifestations associated with intermittent infections. At
every visit, patients were asked whether they had been taking the
zinc supplements daily to promote compliance. We also assessed
the best-corrected visual acuity using Early-Treatment Diabetic
Retinopathy Study (ETDRS) charts at every visit. In addition, we
imaged the retinas using high-resolution spectral-domain optical
coherence tomography (SD-OCT) to detect active neovascular
manifestation of AMD. We performed color fundus photography
at baseline to assist in AMD grading based on the 5-grade Clinical
Age-Related Maculopathy Staging (CARMS) classification scale
[38].
Complement measurements and genotyping in AMD
patients
Serum was prepared by coagulation at room temperature and
after centrifugation the samples were stored at 280uC within one
Figure 1. Flow diagram of patient inclusion.
doi:10.1371/journal.pone.0112682.g001
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hour after collection. C3 and C3d were measured in serum
samples as described [39,40]. All C3 and C3d measurements in
this study were performed in a single experiment, except for the
final sample in months 14–22. C5a was measured by ELISA at a
1/10 dilution using a commercially available development kit
(DuoSet) for human complement component C5a (R&D Systems,
Minneapolis, USA). All the samples collected at baseline to month
5 were measured in a single run.
The CFH (Y402H; rs1061170) and ARMS2 (A69S;
rs10490924) SNPs were genotyped as described [41]. Serum zinc
concentration was measured by atomic absorption spectroscopy
with the spectrophotometer 1100 B from Perkin Elmer. CRP
levels were measured by Abbott Architect C16000 system. The
immunoturbidimetric test for CRP was provided by Abbott
Diagnostics (Abbott Diagnostics).
In vitro hemolytic assays and membrane attack complex
(MAC) deposition on RPE cells
We designed in vitro experiments to provide evidence of a
direct effect of zinc on the complement pathway. Human serum
was prepared from blood of several healthy volunteers after
written informed consent had been obtained with the specific
permit (418/2008) from the ethics committee of Lund University.
Commercially available rabbit erythrocytes (Ha˚tunalab, Bro,
Sweden) were washed in 2.5 mM veronal buffer pH 7.3,
supplemented with 70 mM NaCl, 140 mM glucose, 0.1% porcine
gelatin and 7 mM MgCl2. Different concentrations (0–64 mM) of
zinc sulphate (Merck) were pre-incubated with 2% serum in the
same buffer for 1.5 h at 37uC, followed by 1 h incubation at 37uC
together with the erythrocytes. The amount of lysed erythrocytes
was determined from the amount of released hemoglobin at
405 nm using Cary 50 MPR microplate reader (Varian).
To study the effect of zinc on membrane MAC deposition on
human RPE cells subjected to oxidative stress, RPE cells (ARPE-
19, ATCC) were cultured in DMEM/F12 media (HyClone),
supplemented with 10% FCS (Gibco) and antibiotics (HyClone).
After detachment using trypsin, the cells were incubated in
medium containing 10 mM H2O2 for 2 h at 37uC, to mimic
oxidative damage and make them amenable to attack from
complement [42,43]. After washing with PBS, the cells were
incubated with 5% human serum, together with 0–250 mM zinc
sulphate, in the veronal buffer defined above, for 1 h at 37uC. The
amount of MAC deposited on the RPE cells was detected using a
monoclonal C9 neoepitope antibody (aE11, Hycult), which only
recognizes C9 in the C5b-9 complex, followed by a FITC-
conjugated secondary antibody and flow cytometric analysis
(Partec).
Statistical analysis
A sample size of 70 was calculated to detect a decrease in serum
C3d/C3 of 10% after 3 months, using the complement levels from
a previous study to estimate variation [30], with a= 0.05 and a
power of 80%.
Change in serum zinc, change in C3d/C3 ratio and change in
C5a over the entire study period (0 to 14–22 months) were all
modeled separately. Changes in serum zinc concentration were
analyzed using a linear mixed-effects model with zinc concentra-
tion as the dependent variable. To make optimal use of repeated
measures and to allow for correction of baseline differences,
changes in C3d/C3 and C5a levels level were analyzed using
linear mixed-effects models with C3d/C3 ratio or C5a as the
dependent variable. The interaction between time and baseline
complement levels was included in a linear mixed-effects model to
study any baseline effects. To illustrate the effect of the baseline
C3d/C3 ratio we plotted the course of the C3d/C3 ratio for 3
groups with different baseline ratios using the raw data. In a recent
study we measured C3d/C3 levels in 150 unaffected control
subjects of 65 years and older [30], and we used the mean value
(1.5) and standard deviation (0.6) to determine the cut-off points.
The cut-off values for the different groups were selected by taking
the mean C3d/C3 ratio and one standard deviation above and
below the mean of the healthy control group. Our population was
not large enough to create groups of individuals with two standard
deviations above and below the mean. This resulted in the
following three groups: 1. patients with baseline ratio $2.1
(n = 16); 2. patients with ratios between 1.5–2.1 (n = 29); and 3.
patients with ratio ,1.5 (n = 31). Only very few subjects (n = 3)
had a baseline ratio more than one standard deviation below the
mean, so these individuals were included in group 3. The
associations between the complement levels throughout the study
and CFH and ARMS2 genotype, age, gender, CRP level and zinc
level were also studied using a linear mixed-effects model. In the
final models for the change in zinc, C3d/C3 and C5a, only
significant predictors were used (p,0.05). For the final serum zinc
and C5a models this meant the inclusion of time and baseline
values as the independent variables. In the final C3d/C3 model
the independent variables were time, baseline C3d/C3 and the
interaction between time and baseline C3d/C3.
To further explore the relationship between baseline comple-
ment catabolism and other patient characteristics at baseline, we
assessed the associations of age and baseline visual acuity with
baseline C3d/C3 ratio and C5a using the Pearson correlation and
the Spearman’s rank correlation coefficient. The difference in
baseline complement catabolism between different genotypes was
assessed using one-way ANOVA.
Because patients often display different stages of AMD in each
eye, we created five groups for both eyes. These groups were based
on the CARMS classification as follows: (CARMS grade 2:2),
small drusen and/or RPE changes in both eyes; (CARMS grade
3:3), large drusen and/or drusenoid RPE detachment in both eyes;
(CARMS grade 2:4–5), small drusen and/or RPE changes in one
eye and geographic atrophy or choroidal neovascularisation in the
other eye; (CARMS grade 3:4–5), large drusen and/or drusenoid
RPE detachment in one eye and geographic atrophy or choroidal
neovascularisation in the other eye; and (CARMS grade 4–5:4–5),
geographic atrophy or choroidal neovascularisation in both eyes.
The association between baseline systemic complement catabolism
and CARMS classification was tested using one-way ANOVA
with a post-hoc Bonferroni correction. The correlation between
baseline visual acuity and CARMS was tested using the Spear-
man’s rank correlation coefficient.
Visual acuity changes during the course of the study were
assessed by generalized estimated equations (GEE). The GEE
model estimated the probability of low vision (LogMAR ,0.5)
versus high vision (LogMAR .0.5), with time and baseline C3d/
C3 ratio as predictors. Data for the hemolytic assay and the RPE
cell assay were analyzed using one-way ANOVA with Dunnett’s
multiple comparison test.
Reported p-values are two-sided, and differences were consid-
ered to be statistically significant if lower than 0.05. All statistical
analyses were performed using SPSS, version 18.0.
Results
To evaluate the effect of receiving zinc supplements on systemic
complement catabolism, AMD patients received oral zinc
sulphate. The baseline characteristics of the study population are
presented in Table 1. Serum zinc concentration increased
Zinc Supplementation Inhibits Complement Activation in AMD
PLOS ONE | www.plosone.org 4 November 2014 | Volume 9 | Issue 11 | e112682
significantly during the supplementation period (p,0.001) and
returned to baseline levels two months after the zinc supplements
were discontinued (Figure 2). The mean complement activation
level, defined as the C3d/C3 ratio, in the 72 patients showed
tendency to decline (albeit not significantly; p = 0.149) during the
three months of zinc supplementation (Figure 2). From month five
onwards, 36 patients indicated they had been using over-the-
counter zinc supplements, but generally in lower dosages than
used in this study.
Exploration of effect of zinc supplementation on
complement catabolism
We conducted further exploratory analyses whether zinc
supplementation may have different effects within patients with
different levels of baseline complement catabolism defined as
C3d/C3 ratio. In this analysis, we observed a strong interaction
between baseline C3d/C3 ratio and change in C3d/C3 ratio
during zinc supplementation (p,0.001). The AMD patients with
relatively high baseline levels of serum complement catabolism
exhibited a more pronounced decline in their C3d/C3 ratio
during the administration of zinc sulphate, compared to those
AMD patients with lower baseline levels. After the zinc
supplementation period, the decline in C3d/C3 ratio remained
at this lower level for the following two months. Measurements
performed at least nine months later (in months 14–22) showed
that complement activation had returned to baseline levels. The
AMD patients who already had a relatively low C3d/C3 ratio at
baseline showed no decline in C3d/C3 ratio throughout the
treatment period. Figure 3 illustrates the course of serum C3d/C3
ratio over time in three groups with different baseline C3d/C3
ratios. The statistical model was not based on these cut-off points.
There was no significant association between C3d/C3 ratio and
age or gender throughout the course of the study. C5a levels
decreased significantly over the three-month supplementation
period (p = 0.019) (Figure 4). We observed a similar baseline effect
for the course of C5a levels, however, the interaction between
baseline and time was not significant and therefore not included in
the final model (p = 0.065).
Association between the stage of AMD and serum
complement catabolism
We further analyzed the clinical characteristics of AMD patients
with a relatively high baseline complement catabolism. Higher
baseline C3d/C3 ratio was significantly associated with younger age
(r =20.33, p = 0.005) and better visual acuity (OD: r = 0.25,
p = 0.031 and OS: r = 0.36, p = 0.002). Also, baseline C3d/C3 ratio
was associated with the CARMS classification based on both eyes
(p = 0.010). Post hoc analysis revealed that patients with large drusen
and/or drusenoid RPE detachment in one eye and geographic
atrophy or choroidal neovascularization in the other eye (3:4–5) had
higher baseline complement catabolism compared to geographic
atrophy or choroidal neovascularization in both eyes (4–5:4–5)
(Table 2). There was no association with baseline C5a and age
(r = 0.068, p = 0.583), visual acuity (OD: r =20.110, p = 0.381 and
OS: r =20.023, p = 0.855) or the CARMS classification based on
both eyes (p = 0.947). C3d/C3 ratio and C5a levels were measured
in separate experiments and were not correlated (r = 0.086,
p = 0.490). As expected, baseline visual acuity for each eye was
strongly associated with the CARMS classification per eye (OD:
r =20.69, p,0.001 and OS: r =20.65, p,0.001) (Table S1).
Correlation between the serum complement catabolism
and the genotype
The baseline C3d/C3 ratios did not differ significantly between
wildtype/heterozygous Y402H CFH genotype and the homozy-
gous Y402H genotype (p = 0.934) nor between ARMS2 genotypes
(p = 0.729). There was also no difference in baseline C5a between
CFH (p = 0.597) and ARMS2 genotypes (p = 0.412). Change in
Table 1. The baseline characteristics of the study population.
Baseline characteristics AMD, n=72
Mean age – years 6 SD 73.968.3
Sex, male – No. (%) 29 (40.3)
Visual acuity OD – median (1st–3rd quartile) 20/83 (20/400–20/25)
Visual acuity OS – median (1st–3rd quartile) 20/55 (20/333–20/26)
Mean C3d/C3 ratio 6 SD 1.6560.69
Mean zinc level – mmol/l 6 SD 13.3362.83
CFH (Y402H; rs1061170) genotypes, No. (%)
CFH TT genotype (wildtype) 1 (1.4)
CFH CT genotype 36 (50.0)
CFH CC genotype 34 (47.2)
ARMS2 (A69S; rs10490924) genotypes, No. (%)
ARMS2 GG genotype (wildtype) 19 (26.4)
ARMS2 TG genotype 30 (41.7)
ARMS2 TT genotype 22 (30.6)
Serum C-reactive protein (CRP), No. (%)
,5 – mg/l 52 (72.2)
5–15 – mg/l 18 (25.0)
16–45 – mg/l 2 (2.8)
SD= Standard deviation, visual acuity in Snellen.
doi:10.1371/journal.pone.0112682.t001
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Figure 2. Serum zinc concentration and C3d/C3 ratio throughout the study period. During the three months daily zinc supplementation,
serum zinc concentration increased significantly (p,0.001). After zinc supplementation was discontinued, the serum zinc levels returned to baseline
levels within 2 months. The C3d/C3 ratio showed non-significant decline during zinc supplementation (p = 0.149).
doi:10.1371/journal.pone.0112682.g002
Figure 3. The effect of zinc supplementation on patients with different level of complement catabolism at baseline. The patients with
high serum complement catabolism had a steeper decline in C3d/C3 ratio during the administration of zinc sulphate (p,0.001).
doi:10.1371/journal.pone.0112682.g003
Zinc Supplementation Inhibits Complement Activation in AMD
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e112682
C3d/C3 ratio or C5a levels were not related to CFH or ARMS2
genotypes.
Intermittent infections and the C3d/C3 ratio
Serum CRP levels were measured at every visit and were not
significantly associated with the C3d/C3 ratio (p = 0.168) nor the
C5a levels (p = 0.942). Questionnaires demonstrated that antibi-
otics were prescribed in 10 patients during the study period. Use of
antibiotics was not related to increased CRP levels, increased body
temperature or elevated C3d/C3 ratio (data not shown) in these
individuals.
Effect of zinc on complement catabolism in vitro
To demonstrate the in vitro effect of zinc on the complement
activity of human serum and to better understand the effect
observed in vivo in the patients, we performed an alternative
pathway hemolytic assay. Results showed that zinc sulphate
inhibits the lysis of rabbit erythrocytes in a dose-dependent
Figure 4. C5a concentration throughout the study period. The C5a levels decreased significantly during the three months of zinc
supplementation and returned to baseline level within 2 months after the cessation of zinc supplementation.
doi:10.1371/journal.pone.0112682.g004
Table 2. Association between the stage of AMD and serum complement catabolism.
Clinical Age-Related Maculopathy Staging (CARMS)
for both eyes
Mean C3d/C3
ratio (SE) No. (%) p*
Grade 2 in both eyes (2:2) 1.64 (0.30) 4 (5.6) 1.000
Grade 2 in the first eye and grade 4 or 5 in the
second eye (2:4–5)
1.69 (0.31) 9 (12.7) 1.000
Grade 3 in both eyes (3:3) 1.86 (0.17) 10 (14.1) 0.263
Grade 3 in the first and stages 4 or 5 in the second
eye (3:4–5)
2.01 (0.20) 19 (26.8) 0.006
Grades 4 or 5 in both eyes (4–5:4–5) 1.32 (0.06) 29 (40.8) Ref.
Compared to the patients with intermediate AMD in one eye and late AMD in the other eye (CARMS stage 3:4–5), the patients who had late AMD in both eyes (CARMS
4–5:4–5) had significantly lower C3d/C3 levels (p = 0.006).
*p-value from one-way ANOVA with post hoc Bonferroni correction.
doi:10.1371/journal.pone.0112682.t002
Zinc Supplementation Inhibits Complement Activation in AMD
PLOS ONE | www.plosone.org 7 November 2014 | Volume 9 | Issue 11 | e112682
manner (Figure 5A). Retina is exposed to high levels of oxidative
stress from light exposure and metabolic processes [44]. We tested
in vitro whether zinc could also protect the RPE from a oxidative
stress related damage from the complement system. The test
results show that the amount of MAC deposited on RPE cells
exposed to oxidative stress can be reduced in a dose dependent
manner by zinc sulphate (Figure 5B–C). In the negative controls,
zinc and serum were omitted.
Discussion
In the past decade, it has become increasingly clear that
complement-mediated inflammation plays a fundamental role in
the etiology of AMD [18,45]. All current therapies for treating
neovascular AMD are designed to reduce the ongoing VEGF
stimulus–and hence inhibit the growth of new vessels–but do not
address the underlying pathology. Moreover, no effective therapy
has been developed for treating early AMD or geographic
atrophy. The discovery of complement as a major contributing
factor to AMD pathogenesis has sparked considerable interest in
this system as a potential therapeutic target, and various
complement inhibitors are currently being tested in clinical trials
[14,15].
Our findings suggest that increased complement catabolism,
defined as the C3d/C3 ratio, in AMD patients can be reduced by
the daily oral administration of 50 mg zinc sulphate. However, the
effect of complement inhibition seemed to be limited to patients
with a high baseline level of complement catabolism. The C3d/C3
ratio returned to its baseline value after the supplementation
period, indicating a reversible effect of zinc supplementation on
complement activation. Continuous zinc supplementation may
therefore be necessary to inhibit complement activity over longer
periods of time. Approximately 50% of patients indicated they had
been using zinc supplements during the period before the last
measurement. However, the zinc dosage and possibly compliance
in these patients was apparently too low to exert a clear effect on
complement levels.
We then linked the degree of serum complement activation to
the clinical stages of AMD and found that the level of serum
complement activation is correlated with patients having large
drusen and/or drusenoid RPE detachment. It has been demon-
strated that 42% of patients with drusenoid RPE detachment
progress to end-stage AMD and develop profound and irreversible
visual loss within five years [46]. The AREDS1 study showed that
this group in particular benefits from zinc plus antioxidant
supplementation. Our results suggest that this may be related to
increased activation of the alternative complement pathway in this
group, which would support the notion that patients with large
drusen and/or drusenoid RPE detachment should receive
supplements. Although correlation coefficients were modest,
higher complement levels at baseline were mostly observed in
younger patients with better visual acuity, corresponding with less
advanced disease. This could indicate that the use of supplements
should not be postponed until more advanced stages of the disease.
C5a showed a significant decrease during zinc supplementation,
indicating that zinc inhibition of the complement pathway can also
be detected further downstream. We observed a similar pattern of
increased inhibitory effect in patients with higher baseline C5a
levels, but this was not as profound as for the C3d/C3 ratio. This
could be explained by the more unstable nature of C5a as
compared to the C3d/C3 ratio which corrects for intrapersonal
fluctuations. C5a returned to its baseline value within 2 months
after the supplementation period also suggesting a reversible effect
of zinc on C5a.
The exact role of genotype in the response to zinc and
antioxidant supplements remains unclear. The Rotterdam study
showed that high dietary zinc intake reduces the risk of AMD
associated with the CFH Y402H variant, suggesting a relationship
between zinc and this genotype [33]. A recent subgroup analysis,
utilizing data from the AREDS study, showed that the response to
zinc and antioxidants may be influenced by CFH and ARMS2
genotype. Their results suggested that patients carrying the CFH
Y402H risk allele have no benefit from zinc supplementation on
the 10-year disease progression [47]. In previous studies by
AREDS study researchers on the interaction between genotype
and treatment response, they found that the AREDS supplements
may be less effective in reducing progression in carriers of the
CFH risk allele [48]. But in a later publication they could not
corroborate the interaction and could not find any relation with
response to zinc or antioxidants and genotype [49]. Notably, a
biochemical study of zinc and factor H showed that the interaction
between zinc and the factor H protein was not influenced by the
CFH Y402H variant [50]. In our study, genotype did not have an
effect on baseline or change of complement activation levels.
Given the small number of study participants our study probably
lacks the power to detect a possible interaction between CFH or
ARMS2 genotype and zinc supplementation.
Changes in C3 activation over time can also be caused by
various factors related to immune defense in case of infection [51].
Since serum CRP levels were not significantly associated with
C3d/C3 ratio, it is unlikely that the observed change in
complement catabolism can be ascribed to an intermittent
Figure 5. The effect of zinc on the hemolytic activity of human serum and on the membrane attack complex (MAC) deposition on
retinal pigment epithelial (RPE) cells. (A) Zinc sulphate inhibits the lysis of rabbit erythrocytes in a dose-dependent manner. (B–C) the amount
of MAC deposited on RPE cells exposed to oxidative stress can be reduced in a dose dependent manner by zinc. *p,0.05 and ***p,0.001.
doi:10.1371/journal.pone.0112682.g005
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infection. Data obtained from a general physical examination and
a questionnaire aimed at identifying clinical manifestations of
intermittent infections also did not point to an infectious cause for
the change in complement levels in these AMD patients. Finally, it
is unlikely that the study results were influenced by the statistical
phenomenon of ‘regression to the mean’ because the C3d/C3
ratio returned to baseline levels for after discontinuation of zinc
administration.
In further support of our hypothesis that zinc administration
affects complement catabolism, we demonstrated in vitro that zinc
sulphate directly inhibits complement activation in human serum
in a dose-dependent manner. In addition, we demonstrated that
during oxidative challenge the presence of zinc sulphate dimin-
ishes MAC deposition on RPE cells, thereby preventing comple-
ment-mediated cytolysis and apoptosis. This implies that zinc not
only has the ability to reduce systemic activation of the alternative
complement pathway, but may also diminish complement
activation locally on RPE cells. Important to note is that zinc
concentrations were in physiological levels [44,52], and therefore
have biomedical significance. A previous biochemical study
showed that oligomerization of the CFH protein occurs in the
presence of zinc, theoretically leading to increased complement
activation [53]. A more recent biochemical study from researchers
of the same study group demonstrated that factor H-C3b
complexes are precipitated by zinc which would inhibit comple-
ment activation [54]. Thus we cannot pinpoint the exact
molecular mechanism behind our observations, however, we can
conclude that zinc inhibits systemic complement activation and
local MAC deposition preventing RPE cell damage.
This study has some limitations that should be addressed. A
relatively small number of subjects were included, and zinc was
administered for a relatively brief period of time. Patient
compliance was monitored through questionnaires, which could
potentially underestimate zinc intake. However, a steep increase in
serum zinc following the initiation of treatment indicated that
supplementation had been successful. Because of the slow natural
progression of AMD, this study was never designed to measure a
direct protective effect of zinc on visual acuity. Larger patient
cohorts and a longer period of zinc supplementation should also be
studied to corroborate and extend our findings.
In summary, in our study increased levels of serum complement
catabolism correlates with the stage of AMD. Our study
demonstrate that increased levels of complement catabolism can
be normalized by the daily oral administration of 50 mg zinc
sulphate. Findings from the present study might explain how zinc
slows AMD progression in subgroups of patients with AMD.
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